Philippines FDA approves first ever generic version of Pfizer anti-Covid pill

Manila (Philippines), January 25: The Philippines Food and Drug Administration (FDA) has approved the world’s first generic version of Pfizer’s anti-Coronavirus pill Paxlovid, just days after the original was granted Emergency Use Authorisation (EUA) by the US FDA.

The Philippines FDA has approved the department of health’s application for a compassionate special permit application for the first generic version of Paxlovid that has been launched by Beximco Pharmaceuticals, a leading generic drugmaker from Bangladesh.

Philippines-based Pharmaceutical company Biocare Lifesciences Inc would be the distributor and importer of a generic drug, which would be sold under the brand name Bexovid in the Philippines.

According to Pfizer, the risk of hospitalisation or death is reduced by 89% when Paxlovid is given within three days of the onset of symptoms and by 88% when given within five days of the onset of symptoms. The treatment, a combination of Nirmatrelvir and Ritonavir tablets, is given together twice a day for five days and is recommended for treatment of mild to moderate cases of Covid-19.

Pfizer data also suggests the drug remains effective against the faster-spreading Omicron variant of the Coronavirus, which is driving the latest surge in Covid-19 cases globally.

“The approval by the Philippines FDA will make Bexovid accessible to Covid-19 patients in the country and add another treatment protocol to the existing drugs. We plan to import 20,000 to 30,000 courses of Bexovid initially and expect the supplies to begin in the first week of February. Bexovid is expected to be priced 50-60% cheaper than the original Pfizer drug, making it an affordable option,” said Dileep Tiwari, Managing Director, Biocare Lifesciences, during an interview with CNN.

Bexovid is recommended as an at-home treatment to help reduce the severity of the infection. The drug has the potential to eliminate many hospitalizations, thus helping reduce the strain on the healthcare infrastructure.

“Bexovid is not meant for patients who are hospitalised. Any patient who is Covid-19 positive can buy the drug from hospitals once supplies begin,” said Mr. Tiwari in a CNN interview.

Separately, Bangladesh’s Directorate General of Drug Administration has also granted EUA for Bexovid to treat mild-to-moderate Covid-19 cases in patients aged 12 and above.

Comments are closed.

Business News Finance PNN News Press Release

Interim Budget 2024: IMS Ghaziabad (University Courses Campus)’s Perspective on Catalyzing Research, Innovation, and Entrepreneurship

New Delhi (India), February 23: Over the past few years, India has seen major changes in perhaps one of the most unexpected areas; as the Indian education system grows and adapts technology on a greater level, this assimilation is leaving a positive impact in eliminating educational barriers nationwide. For instance, In 2023, India witnessed a […]

Read More
Anubhav Agarwal Budget 2024 Budget Buzz Business News Dharmesh Mehta Dr. Aamir Junaid Ahmad Finance PNN News Press Release Zeeshaan Pathan

Budget Buzz: Leading Entrepreneurs Sound Off on India’s Fiscal Roadmap

New Delhi (India), February 17: The annual Union Budget unveils its plans for the Nation’s economy, and naturally, leading entrepreneurs have their keen observations to share. This curated list captures the diverse reactions of prominent business minds, offering valuable insights into how the budget might impact different sectors and the overall entrepreneurial ecosystem. Dharmesh Mehta […]

Read More
Business Finance PNN News Press Release

5 Skills Required to Bag Business Analytics MBA Jobs in 2024

New Delhi (India), February 16: In the demanding market of business analytics, there is an increasing need for specialists with advanced skills. Now that we are in 2024, the competition to secure employment in Business Analytics MBA programs has intensified more than in previous times. To secure a seat in PGDM(MBA^) Admissions, candidates need to possess […]

Read More